Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer.

Meng YuanYirui ZhaiYu MenMaoyuan ZhaoXin SunZeliang MaYongxing BaoXu YangShuang SunYunsong LiuWanting ZhangZhouguang Hui

Published in: Oxidative medicine and cellular longevity (2022)

Our findings indicate that anlotinib might be a potential synergistic treatment for radioimmunotherapy to achieve better antitumor efficacy in NSCLC patients by potentiating the tumor immune microenvironment.

Keyphrases

high dose
stem cells
end stage renal disease
ejection fraction
small cell lung cancer
newly diagnosed
low dose
prognostic factors
stem cell transplantation
risk assessment
patient reported